[go: up one dir, main page]

AU2002311573A1 - Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer - Google Patents

Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer

Info

Publication number
AU2002311573A1
AU2002311573A1 AU2002311573A AU2002311573A AU2002311573A1 AU 2002311573 A1 AU2002311573 A1 AU 2002311573A1 AU 2002311573 A AU2002311573 A AU 2002311573A AU 2002311573 A AU2002311573 A AU 2002311573A AU 2002311573 A1 AU2002311573 A1 AU 2002311573A1
Authority
AU
Australia
Prior art keywords
ecp
polymorphism
cancer
treatment
cationic protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002311573A
Inventor
Per Venge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002311573A1 publication Critical patent/AU2002311573A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27001—Ribonuclease T2 (3.1.27.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002311573A 2001-05-08 2002-05-08 Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer Abandoned AU2002311573A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0111194.7 2001-05-08
GB0111194A GB0111194D0 (en) 2001-05-08 2001-05-08 Sequences
PCT/IB2002/002555 WO2002089829A2 (en) 2001-05-08 2002-05-08 Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer

Publications (1)

Publication Number Publication Date
AU2002311573A1 true AU2002311573A1 (en) 2002-11-18

Family

ID=9914200

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002311573A Abandoned AU2002311573A1 (en) 2001-05-08 2002-05-08 Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer

Country Status (3)

Country Link
AU (1) AU2002311573A1 (en)
GB (1) GB0111194D0 (en)
WO (1) WO2002089829A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113373218A (en) * 2021-08-04 2021-09-10 杭州浙大迪迅生物基因工程有限公司 Primer group and kit for detecting mRNA expression of human eosinophil cationic protein

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2600108A1 (en) * 2004-03-03 2005-09-15 Chaker N. Adra Granulocyte subtype-selective receptors and ion channels and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001706D0 (en) * 2000-05-09 2000-05-09 Astrazeneca Ab sequences

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113373218A (en) * 2021-08-04 2021-09-10 杭州浙大迪迅生物基因工程有限公司 Primer group and kit for detecting mRNA expression of human eosinophil cationic protein

Also Published As

Publication number Publication date
WO2002089829A2 (en) 2002-11-14
WO2002089829A3 (en) 2003-05-30
GB0111194D0 (en) 2001-06-27

Similar Documents

Publication Publication Date Title
AU2002352799A8 (en) Methods for evaluating drug-resistance gene expression in the cancer patient
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
AU2002368044A1 (en) Co-stimulatory molecules
AU2001288101A1 (en) Ultrasonic beauty treatment probe
AU2002364607A1 (en) Novel ligand involved in the transmigration of leukocytes .
MXPA03008582A (en) Agents and methods for treatment of cancer.
AU2002306600A1 (en) Sperm protein 17 for the diagnosis and treatment of cancer
AU2002308642A1 (en) Methods for treating cancer
AUPR974001A0 (en) Liquid heater
AP2004003070A0 (en) The method of treating cancer.
MXPA03007036A (en) Method of cancer therapy.
AU2002334891A1 (en) Tumor targeted photodiagnostic-phototherapeutic agents
AU2002311573A1 (en) Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer
AU3556800A (en) Expression of dna or proteins in (c. elegans)
AU2003263036A1 (en) SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AU2003249999A1 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours
AU2002302838A1 (en) Cancer associated protein
AU2001292788A1 (en) Remote-on-the-spot credit processing
AU2002366631A1 (en) Human prostate cancer candidate protein 1
AU2002242505A1 (en) Tumor associated proteins
AU2002357468A1 (en) Use of 2-acylindoles in the treatment of tumors
AU2001273081A1 (en) Peptide combination for the treatment of cancer
AU2002234906A1 (en) Fluid treatment system
HK1052013A (en) Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer
AU2002303821A1 (en) Aryl-8-azabicyclo(3.2.1)octanes for the treatment of depression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase